Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Net Margin (2016 - 2025)

Oramed Pharmaceuticals filings provide 8 years of Net Margin readings, the most recent being 382.1% for Q1 2025.

  • Quarterly Net Margin changed N/A to 382.1% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 3587.55% through Dec 2025, changed N/A year-over-year, with the annual reading at 3587.55% for FY2025, N/A changed from the prior year.
  • Net Margin hit 382.1% in Q1 2025 for Oramed Pharmaceuticals, down from 194.81% in the prior quarter.
  • Across five years, Net Margin topped out at 194.81% in Q2 2023 and bottomed at 1565.32% in Q1 2022.
  • Average Net Margin over 4 years is 920.42%, with a median of 928.95% recorded in 2022.
  • Peak annual rise in Net Margin hit 136795bps in 2023, while the deepest fall reached 105556bps in 2023.
  • Oramed Pharmaceuticals' Net Margin stood at 822.72% in 2021, then tumbled by -57bps to 1290.71% in 2022, then soared by 85bps to 194.81% in 2023, then plummeted by -96bps to 382.1% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Net Margin are 382.1% (Q1 2025), 194.81% (Q2 2023), and 509.76% (Q1 2023).